Drug intelligence / Profile preview

ORM-14540

Development stage: Phase 1
Lead developer: Orion
Modality: Small Molecules

Overview

ORM-14540 is an investigational small molecule drug developed by Orion Oyj. It acts as an antagonist of the alpha-2C adrenergic receptor (α2C-AR). The compound was evaluated in early phase clinical studies to determine its pharmacokinetic properties in healthy volunteers. No approved indications, adverse events, or FDA designations are reported for this agent. Its mechanism of action involves blocking α2C adrenergic receptors, which may have implications for neurological or psychiatric conditions, though no specific therapeutic area has been disclosed[1][2][3][5].

Targets

ADRA2C (α2C)

Beyond the preview

Go deeper on ORM-14540.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORM-14540.

Explore the full profile